Get startedLog in
    Picture of Corcept Therapeutics Incorporated logo

    CORT — Corcept Therapeutics Incorporated News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousLarge CapHigh Flyer
    All News

    Brief: FDA Reviews Corcept’s NDA for Relacorilant in Drug-Resistant Ovarian Cancer

    Picture of Corcept Therapeutics Incorporated logoCorcept Therapeutics Incorporated
    10/09/2025 13:01
    Sept 10 (Reuters) - Corcept Therapeutics Inc CORT.O:

FDA FILES CORCEPT’S NEW DRUG APPLICATION FOR RELACORILANT AS A TREATMENT FOR PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER

CORCEPT THERAPEUTICS INC - FDA ASSIGNS PDUFA DATE OF JULY 11, 2026 FOR RELACORILANT

Source text: ID:nBwrWrvVa

Further company coverage: CORT.O

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Corcept Therapeutics Incorporated

    See all news